Navigation Links
Can an over-the-counter vitamin-like substance slow the progression of Parkinson's disease?

Rush University Medical Center is participating in a large-scale, multi-center clinical trial in the U.S. and Canada to determine whether a vitamin-like substance, in high doses, can slow the progression of Parkinson's disease, a neurodegenerative disorder that affects about one million people in the United States.

"At present, the very best therapies we have for Parkinson's can only mask the symptoms they do not alter the underlying disease," said neurologist Dr. Katie Kompoliti, a specialist in movement disorders. "Finding a treatment that can slow the degenerative course of Parkinsons's is the holy grail of Parkinson's research."

The substance being tested, called coenzyme Q10, is produced naturally in the body and is an important link in the chain of chemical reactions that produce energy in mitochondria, the "powerhouses" of cells. The enzyme is also a potent antioxidant a chemical that "mops up" potentially harmful chemicals generated during normal metabolism.

Several studies have shown that Parkinson's patients have impaired mitochondrial function and low levels of coenzyme Q10. Moreover, laboratory research has demonstrated that coenzyme Q10 can protect the area of the brain damaged in Parkinson's.

The Phase III clinical trial, a large, randomized study with a control group, follows an earlier investigation that tested several doses of coenzyme Q10 in a small group of patients with early-stage Parkinson's disease. The highest dose, 1,200 mg, appeared promising. Over the course of 16 months, patients taking this dose experienced significantly less decline than other patients in motor (movement) function and ability to carry out activities of daily living, such as feeding or dressing themselves.

But researchers involved in the study, including Kompoliti, were cautious about their findings, citing the need for a more extensive review to confirm the results.

In the present trial, funded by the National Institutes of Health and the National Institute of Neurological and Disorders and Stroke, 600 patients will be enrolled at 60 centers in the U.S. and Canada. Two dosages of coenzyme Q10 are being tested,1,200 mg and 2,400 mg, delivered in maple nut-flavored chewable wafers that also contain vitamin E.

Participants in the study will be evaluated periodically over 16 months for symptoms of Parkinson's disease, including tremor, stiffness of the limbs and trunk, impaired balance and coordination, and slowing of movements. They will also be assessed for ability to perform daily activities, overall quality of life, and need to take medications to alleviate symptoms.


Contact: Sharon Butler
Rush University Medical Center

Related biology news :

1. Airway cells use tasting mechanism to detect and clear harmful substances
2. Natural brain substance blocks weight gain in mice, UT Southwestern researchers discover
3. UI researchers find potentially toxic substance present in Chicago air
4. Substance found in fruits and vegetables reduces likelihood of the flu
5. Argyrin: Natural substance raises hope for new cancer therapies
6. Tests show LLNL detection instrument can monitor the air for all major terrorist threat substances
7. Substance in red wine found to keep hearts young
8. Researchers develop new ultrasensitive assay to detect most poisonous substance known
9. Motor neuron disease and toxic substances: Possible link?
10. New method reveals substances on surfaces of any kind
11. Green tea may affect prostate cancer progression
Post Your Comments:
(Date:11/17/2015)... 17, 2015 Paris ... --> Paris , qui s,est ... DERMALOG, le leader de l,innovation biométrique, a inventé le ... et empreintes sur la même surface de balayage. Jusqu,ici, ... l,autre pour les empreintes digitales. Désormais, un seul scanner ...
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/12/2015)... Nov. 11, 2015   Growing need for ... tools has been paving the way for use ... of discrete analytes in clinical, agricultural, environmental, food ... predominantly used in medical applications, however, their adoption ... due to continuous emphasis on improving product quality ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015 Spherix Incorporated (Nasdaq: ... to the fostering and monetization of intellectual property, ... prospective initiatives designed to create shareholder value. ... of Spherix. "Based on published reports, the total ... $50 billion and Spherix will seek to secure ...
(Date:11/30/2015)... , Nov. 30, 2015  HUYA Bioscience International, ... China,s pharmaceutical innovations, today announced it has ... Development Fund (KDDF) to foster collaboration between KDDF and ... and commercialization of healthcare products for the global market. ... an important source of new innovative preclinical and clinical ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announced tighter software integration with MarkLogic, the Enterprise NoSQL database platform provider, ... to drive change. , Smartlogic’s Content Intelligence capabilities provide a robust set ...
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is one ... biomarkers market with pharmaceutical companies and diagnostic ... diagnostic tests. . ... Complete report on global cancer biomarkers market ...
Breaking Biology Technology: